<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923702</url>
  </required_header>
  <id_info>
    <org_study_id>BMGF48979</org_study_id>
    <secondary_id>ISRCTN98283094</secondary_id>
    <secondary_id>REFCTRI-2009 000137</secondary_id>
    <nct_id>NCT00923702</nct_id>
  </id_info>
  <brief_title>Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India</brief_title>
  <official_title>Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr R. Sankaranarayanan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Foundation of India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christian Fellowship Community Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Krebsforschungszentrum (DKFZ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gujarat Cancer &amp; Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jehangir Clinical Development Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MNJ Institute of Oncology &amp; Regional cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rajiv Gandhi Centre for Biotechnology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tata Memorial Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Agency for Research on Cancer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary study hypothesis is that a two-dose human papillomavirus (HPV) vaccine regimen
      would offer similar immunogenicity and protection as that of a three-dose regimen to girls
      against persistent HPV infection and cervical neoplasia caused by HPV types included in the
      vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean titers of serum neutralizing antibodies to vaccine included HPV types (16/18/6/11) at 7, 12, 24, 36, 48 months.</measure>
    <time_frame>5 years from the base-line date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of incident and persistent HPV 16/18/6/11 infection.</measure>
    <time_frame>5 years from the base-line date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of infection by other non-targeted high-risk HPV types.</measure>
    <time_frame>15 years from the base-line date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of HPV 16/18-associated precancerous lesions and cancer.</measure>
    <time_frame>15 years from the base-line date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of cervical neoplasia associated with non-included HPV types.</measure>
    <time_frame>15 years from the base-line date</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Cervical Precancerous Lesions</condition>
  <arm_group>
    <arm_group_label>2 doses of vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants will receive two doses of the vaccine at Day 1 and Day 180.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 doses of vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants will receive three doses of the vaccine at Day 1, Day 60, and Day 180.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)</intervention_name>
    <description>The participants will be randomly allocated in equal numbers to receive either two or three doses of the vaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18. Girls in the two-dose group will receive the vaccine at Day 1 and Day 180, girls in the three-dose group will receive the vaccine at Day 1, Day 60, and Day 180.</description>
    <arm_group_label>2 doses of vaccine</arm_group_label>
    <arm_group_label>3 doses of vaccine</arm_group_label>
    <other_name>Gardasil®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Apparently healthy, ambulant girls aged 10 - 18 years

          -  Unmarried girls

          -  Girls with intact uterus

          -  Resident in the villages chosen for the study

        Exclusion Criteria:

          -  Girls with any severe and/or debilitating illness

          -  Past history of allergy to any medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rengaswamy Sankaranarayanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Agency for Research on Cancer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MNJ Institute of Oncology &amp; Regional Cancer Center</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Foundation of India</name>
      <address>
        <city>Kolkata</city>
        <state>Bengal</state>
        <zip>700031</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gujarat Cancer &amp; Research Institute (GCRI)</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital</name>
      <address>
        <city>Barshi</city>
        <state>Maharashtra</state>
        <zip>413 401</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Center, Tata Memorial Hospital &amp; Cancer Research Inst</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical Development Centre (JCDC) Pvt. Ltd.</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Fellowship Community Health Centre</name>
      <address>
        <city>Ambilikkai</city>
        <state>Tamil Nadu</state>
        <zip>624612</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>International Agency for Research on Cancer</investigator_affiliation>
    <investigator_full_name>Dr R. Sankaranarayanan</investigator_full_name>
    <investigator_title>Head, Early Detection and Precention Section</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

